Physicians' Academy for Cardiovascular Education

Diabetes & Heart Failure: Evaluating novel strategies to address outcomes

Meeting report with video, highlights and slides of PACE-CME symposium held at ESC Heart Failure 2016 in Florence

Meeting Impression: Diabetes & Heart Failure: Evaluating novel strategies to address outcomes

News - May 22, 2016

During the ESC Heart Failure Congress 2016, held in Florence, Italy, PACE-CME organised a satellite symposium on diabetes and heart failure, two debilitating diseases, that aggravate each other when they coexist.

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

News - May 21, 2016
Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

In his presentation professor Sattar. explained the thoughts about the proposed mechanism of action of empagliflozin before, and after the EMPA REG trial

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

News - May 21, 2016
SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

SGLT2 is a glucose transporter and SGLT2 inhibitors can improve glycaemic control. They block kidney reabsorption of filtered glucose and thereby reduce blood glucose levels. So far, only one clinical trial evaluating SGLT2 inhibitor results on CV outcome has been published10. This trial is called the EMPA REG OUTCOME trial in which empagliflozin is evaluated.

Current treatment of Diabetes in Heart Failure

May 21, 2016

The number of acute and chronic HF patients with diabetes (DM) increased tremendously over the last decade. The prevalence of DM in these patients now ranges between 13 and 47% and is even higher in HF patients with preserved ejection fraction (25-33%). Both diseases are deleterious, and prognosis is even worse when the two co-exist. ‘Diabetes and heart failure are fatal twins’, states professor Voors.